Peptonic Medical AB Presents Current Sales Figures

Peptonic Medical AB (publ) (“the Company”) announces current sales figures in connection with the plan hearing being held today at 10:00 AM at the Uppsala District Court. During the hearing, the reconstruction administrator and the Company will present the reconstruction plan. Parts of this presentation, including sales figures for October 2025 and accumulated for the period January through October 2025, have now been published on the Company’s website.

Current sales for October 2025 amount to 2,4 MSEK and for the period January to October 2025 amount to SEK 13.6 million, compared with the forecast of SEK 13.2 million. Further information is available under the sections “Investors” and “Company Reconstruction” on www.peptonicmedical.se.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                           

Email: [email protected]                                                                                     

Phone: +46 70-244 92 07

About Peptonic Medical AB                                        

PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.